Biointerventional solutions for heart failure, chronic myocardial ischemia, and acute myocardial infarction


May 19, 2014
Phase II STOP-HF Trial Shows Excellent Safety Profile, Supports Efficacy for Juventas JVS-100 as Delivered by BioCardia® Helix™ Transendocardial Delivery System

May 7, 2014
RECARDIO Clinical Trial Doses First Patient

March 17, 2014
BioCardia® Receives CE Mark for Morph AccessPro™ Steerable Introducer

November 18, 2013
Phase II TAC-HFT Trial Shows Excellent Safety Profile, Suggests Efficacy, for Transendocardial Delivery of Two Types of Autologous Cells for Ischemic Heart Failure

more news



BioCardia is developing proprietary comprehensive  biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. 

These programs are enabled by the Company's Helix transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.